Market cap
$6 Mln
Recently Viewed
Clear All$2.91
$0.00 (0.00%)As on 24-Apr-2026 16:04EDT
Market cap
$6 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
1.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-1.8 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.1
Debt to Equity
0
Book Value
$0.5
EPS
$-0.9
Face value
--
Shares outstanding
2,142,547
CFO
$-86.58 Mln
EBITDA
$-84.58 Mln
Net Profit
$-87.66 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Can-Fite Biopharma Ltd Sponsored (Israel) - ADR
| -27.3 | -10.2 | -34.9 | -87.7 | -56.4 | -63.4 | -55.4 |
|
BSE Sensex
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Can-Fite Biopharma Ltd Sponsored (Israel) - ADR
| -87.7 | -26.0 | -64.1 | -52.7 | -27.5 | -46.1 | -82.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Can-Fite Biopharma Ltd Sponsored (Israel) - ADR
|
2.9 | 6.2 | 0.4 | -9.9 | -1,595.4 | -179.7 | -- | 1.1 |
| 3.9 | 391.3 | 73.2 | -67.8 | -82.1 | -65.5 | -- | 5.2 | |
| 19.8 | 1,171.8 | 0.0 | -147.4 | -29,734.7 | -150.3 | -- | 6.8 | |
| 28.6 | 1,920.8 | 1,112.2 | 320.9 | -17.8 | 10.5 | 5 | 0.5 | |
| 13.9 | 2,407.3 | 550.0 | 458.1 | -3.3 | 45.9 | 5.3 | 1.9 | |
| 8.7 | 397.4 | 0.0 | -29.0 | -- | -20.4 | -- | 3.0 | |
| 16.7 | 1,178.0 | 403.3 | 22.8 | 3,081.6 | 9.1 | 417 | 4.3 | |
| 3.7 | 668.3 | 4.6 | -201.1 | -4,342.4 | -146.8 | -- | 5.5 | |
| 5.5 | 477.8 | 174.7 | -115.2 | 0.0 | -80.2 | -- | 3.8 | |
| 22.8 | 2,571.6 | 460.2 | -175.5 | -37.7 | -22.6 | -- | 3.6 |
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead... drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel. Read more
Founder, Chief Scientific Officer & Executive Chairperson
Dr. Pnina Fishman Ph.D.
Founder, Chief Scientific Officer & Executive Chairperson
Dr. Pnina Fishman Ph.D.
Headquarters
Ramat Gan
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR is $2.91 (NYSE) as of 24-Apr-2026 16:04 EDT. Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR has given a return of -56.44% in the last 3 years.
Since, TTM earnings of Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.23
|
0.41
|
|
2024
|
-1.74
|
2.52
|
|
2023
|
-1.43
|
1.74
|
|
2022
|
-0.16
|
0.37
|
|
2021
|
-0.23
|
0.20
|
The 52-week high and low of Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR are Rs 88.00 and Rs 2.87 as of 26-Apr-2026.
Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR has a market capitalisation of $ 6 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Can-Fite Biopharma Ltd Sponsored ADR (Israel) - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.